CellCentric’s novel p300/CBP inhibitor, CCS1477 advancing to the clinic

CellCentric has developed a potent, selective, orally bioavailable small molecule inhibitor of p300/CBP. These targets are key regulators of cancer cells, and specifically play a critical role in the progression of the aggressive form of prostate cancer. Key pre-clinical efficacy data on CellCentric’s compound CCS1477 is presented today at GU-ASCO: 2017 Genitourinary Cancer Symposium, Orlando. Castrate resistant prostate cancer (CRPC) remains a significant unmet need, despite recent advances including the adoption of new agents such as Enzalutamide and Abiraterone. CRPC is driven by functional androgen receptor (AR) proteins, and modified AR-splice variants that emerge (2).

View CellCentric's GU-ASCO poster 2017 here.

(2)  Antonarakis et al., (2014) NEJM, 371, 1028-38.